Inclusion Criteria:
  -  Biopsy confirmed diagnosis of SNIP and scheduled to undergo surgical resection;
  -  Age â‰¥ 18 years;
  -  Written informed consent;
  -  Mentally competent person that is able and willing to comply with study procedures.
Exclusion Criteria:
  -  Medical or psychiatric conditions that compromise the patient's ability to give informed consent;
  -  Concurrent uncontrolled medical conditions;
  -  Received an investigational drug within 30 days prior to the dose of bevacizumab-IRDye800CW;
  -  Tumors at sites of which the surgeon would assess that in vivo imaging would not be feasible;
  -  History of myocardial infarction, cerebrovascular accident, uncontrolled cardiac heart failure, significant liver disease or unstable angina within 6 months prior to enrollment;
  -  Inadequately controlled hypertension with or without current antihypertensive medications;
  -  History of infusion reactions to bevacizumab or other monoclonal antibody therapies;
  -  Pregnant or lactating women. Documentation of a negative pregnancy test must be available for women of childbearing potential. Woman of childbearing potential are premenopausal women with intact reproductive organs and women less than two years after menopause;
  -  Lab values that in the opinion of the primary surgeon would prevent surgical resection;
  -  Life expectancy < 12 weeks;